Search results
NEJM Rescinds Embargo Policy Barring Physician-Focused Publications
MedPage Today· 6 days agoNEJM scrapped language on its Media Center homepage that specified access for media producing...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 7 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Boston Scientific’s cardiac rhythm system hits pivotal trial goals
MedTech Dive via Yahoo Finance· 6 days agoThe clinical trial met all its pre-specified six-month safety and effectiveness endpoints, as Boston...
The US Medical Establishment Is Making One of Its Worst Mistakes—Again
The Nation· 6 days agoLast month, the historians Joelle Abi-Rached and Allan Brandt were invited to reflect on The New...
Novo’s Ozempic Slashes Risk of Death in Kidney Disease Study
Bloomberg via Yahoo Finance· 3 days ago(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a...
Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2...
Medical Xpress· 7 days agoThe disease improvements—as measured by a significantly lower annualized rate of acute exacerbations...
Ozempic quells kidney disease risk, study finds
Becker’s Hospital Review· 1 day agoIn a yearslong trial of more than 3,500 participants, Novo Nordisk's Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke ...